Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis

NCT03301883 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT03301883
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03301883 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis
Lead sponsor
Hoffmann-La Roche
Phase
Phase 4
Overall status
Completed
Start date
April 26, 2018
Completion date
August 5, 2022
Enrollment
62 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

juvenile idiopathic arthritis